|2.||Urinary Bladder Neoplasms (Bladder Cancer)
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|5.||Transitional Cell Carcinoma
|1.||Shariat, Shahrokh F: 17 articles (01/2015 - 03/2003)|
|2.||Karakiewicz, Pierre I: 12 articles (03/2013 - 09/2006)|
|3.||Maruyama, Satoshi: 11 articles (05/2015 - 05/2008)|
|4.||Saku, Takashi: 11 articles (05/2015 - 05/2008)|
|5.||Sagalowsky, Arthur I: 11 articles (05/2010 - 11/2005)|
|6.||Cheng, Jun: 10 articles (11/2014 - 05/2008)|
|7.||Rajpert-De Meyts, Ewa: 10 articles (06/2012 - 10/2003)|
|8.||Lerner, Seth P: 10 articles (05/2010 - 03/2003)|
|9.||Lotan, Yair: 10 articles (05/2010 - 09/2006)|
|10.||Yamazaki, Manabu: 9 articles (05/2015 - 06/2011)|
|1.||Mitomycin (Mitomycin-C)FDA LinkGeneric
12/01/1995 - "Therapy of carcinoma in situ with alternating mitomycin C and BCG is more effective than mitomycin C alone. "
01/01/1990 - "Mitomycin C appears to be effective for intravesical treatment of carcinoma in situ of the urinary bladder. "
01/01/2009 - "Topical mitomycin C 2 mg/ml (0.02%) may be a safe and effective treatment for conjunctival intraepithelial neoplasm prior to surgical removal."
01/01/1993 - "Percutaneous perfusion of mitomycin C appears to be one of the effective and safe treatments for the carcinoma in situ of the upper urinary tract."
08/01/2009 - "Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up."
01/01/2004 - "ALA-PDT is effective for premalignant lesions such as mucosal dysplasia and carcinoma in situ of oral cavity. "
09/01/2012 - "Few studies described PDT application in penile oncology for conservative management of carcinoma in situ and premalignant lesions. "
12/01/2013 - "The PDT-induced STAT3 cross-links is significantly higher (P = 0.0033) in SCC than in carcinoma in situ/dysplasia for all light doses. "
09/01/2008 - "In one horse, carcinoma in situ developed 2.5 months after partial surgical excision and PDT, requiring local excision under standing sedation. "
01/01/2008 - "Consecutive patients with BE with HGD or carcinoma in situ treated with PDT were followed with EUS, CT scan and EGD with jumbo biopsies every 1 cm at 3, 4, or 6-month intervals. "
|3.||Doxorubicin (Adriamycin)FDA LinkGeneric
10/24/1991 - "For patients with carcinoma in situ the complete-response probability estimates (i.e., the estimated probability of documented disappearance of disease) were 34 percent for doxorubicin (23 of 67 patients) and 70 percent for BCG (45 of 64 patients) (P less than 0.001); the median times to treatment failure were 5.1 and 39 months, respectively. "
01/01/1986 - "The complete response rate in 41 patients with carcinoma in situ who received BCG was 85%, compared with a complete response rate of only 39% in 46 patients who received adriamycin (p less than 0.001, chi 2). "
01/01/1984 - "Intravesical Adriamycin treatment was given to 22 patients with carcinoma in situ of the urinary bladder. "
01/01/1984 - "Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder."
01/01/1984 - "Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a followup."
|4.||Messenger RNA (mRNA)IBA
08/01/2015 - "Bcl2L12 and its variant mRNA were highly expressed in carcinoma in situ (CIS) samples. "
02/01/2010 - "EL mRNA was abundant in pre-invasive carcinoma in situ (CIS) cells and GCTs, and EL protein was present in the cytoplasm of these cells. "
04/01/2007 - "Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster."
03/01/2006 - "Semi-quantitative detection of hTERT mRNA expression in situ is helpful in differentiated diagnosis of carcinoma in situ and atypical hyperplasia. "
10/01/2007 - "In this study, real-time RT-PCR was used to quantify the mRNA expression of XIAP and Smac/DIABLO in normal testicular tissue (n = 19), testicular carcinoma in situ (CIS; n = 4), testicular seminomas (n = 64) and non-seminomatous germ cell tumours (NSGCT; n = 35). "
|5.||5-aminolevulinic acid hexyl esterIBA
11/01/2013 - "The hexyl aminolevulinate cystoscopy allows to identify a significantly greater number of lesions, including carcinoma in situ, compared to conventional white light cystoscopy. "
01/01/2004 - "Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy."
12/01/2012 - "Since then, PDD with intravesical application of 5-ALA or its ester hexaminolevulinate (Hexvix) has proven to be superior over standard white-light cystoscopy in detection of carcinoma in situ and dysplasia as well as enhancing margins of TCC. "
01/01/2010 - "To evaluate fluorescence cystoscopy with hexaminolevulinate (HAL) in the early detection of dysplasia (DYS) and carcinoma in situ (CIS) in select high risk patients. "
07/01/2007 - "Of a total of 113 carcinoma in situ lesions in 58 patients 104 (92%) were detected by hexaminolevulinate cystoscopy and 77 (68%) were detected by white light cystoscopy, while 5 were detected only on directed visually normal mucosal biopsy. "
04/01/2012 - "The use of iodine staining as a part of otolaryngological examinations may be beneficial for the early detection of CFOM, including carcinoma in situ and micro-invasive SCC. "
04/01/2012 - "Clinical impact of iodine staining for diagnosis of carcinoma in situ in the floor of mouth, and decision of adequate surgical margin."
03/01/2002 - "A strategy is proposed that the high-risk population would be screened by endoscopy with mucosal iodine staining and biopsy of all unstained lesions and diagnosis of severe dysplasia carcinoma in situ, and intra-mucosal carcinoma could be cured by radical mucosectomy. "
01/01/2008 - "The subjects consisted of 50 patients with basal cell hyperplasia, 50 patients with dysplasia, 50 patients with ESCC (12 carcinoma in situ, 38 carcinoma in invasive stage), and 50 controls who were pathologically diagnosed to be normal and whose esophageal mucosa were stained brown by iodine. "
04/01/2000 - "In all ten telomerase positive samples, carcinoma in situ (CIS) was observed in iodine-nonreactive mucosa by light microscopy. "
|7.||DNA (Deoxyribonucleic Acid)IBA
03/01/2009 - "The tolerance and efficacy of mycobacterial cell wall-DNA complex might hold promise for the treatment of carcinoma in situ of the bladder."
01/01/1997 - "Analysis of the nuclear DNA content of pancreatic intraepithelial neoplasms in this study supports our hypothesis. "
12/20/1983 - "Primary carcinoma in situ and dysplasia of the upper urinary tract: microspectrophotometric study of nuclear DNA content."
07/01/1981 - "A detailed histologic and DNA-microspectrophotometric study is presented of 31 lesions selected from 12 of 65 patients with vulvar carcinoma in situ whom the authors have seen. "
01/01/2011 - "A vaginal intraepithelial neoplasm (VAIN2) was found in one of the HPV DNA persistent positive cases. "
11/20/2005 - "In our study, we have analysed the contribution of HPV 16 E6 sequence subtype and allelic variation at human leukocyte antigen (HLA) class II loci to the risk of developing cervical carcinoma in situ. "
08/01/1993 - "The results confirm previously reported studies of the staining of PNA N(-) and blood group-related antigens on carcinoma-in-situ and invasive tumours of urothelial organs. "
09/01/1986 - "In this study, 206 patients were diagnosed as having dysplasia or carcinoma in situ (CIS), and HPV antigen was found in 15% of these patients. "
08/01/2006 - "Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours."
05/01/1999 - "M2A antigen is an oncofetal antigen associated with germ cell neoplasia, present in testis on fetal gonocytes and re-expressed on carcinoma in situ (CIS) and germ cell tumours. "
07/01/1996 - "Bropirimine has been shown to be effective in treating approximately 50% of patients with carcinoma in situ (CIS) of the bladder in recent clinical trials. "
11/01/2005 - "A total of 51 patients with histologic evidence of carcinoma in situ and no prior treatment with BCG or bropirimine were enrolled in a cooperative group multicenter phase II trial. "
11/01/2005 - "A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study."
12/01/1999 - "The study was designed to compare the effects of oral bropirimine with intravesical BCG, the current standard treatment in patients with newly diagnosed bladder carcinoma in situ (CIS). "
12/01/1999 - "Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. "
10/01/2005 - "Tumour size, the co-existence of carcinoma in situ and early tumour recurrence may be prognostic indicators, but the data are at present insufficient."
04/01/2003 - "Neoplastic changes( 8 cases) ranged from intraepithelial neoplasm (PIN) (2 cases), atypical glands (2 cases, both in 7th decade) to adenocarcinomatous changes (2 cases, one each in 6th and 7th decade) were also observed co-existent with BPH. "
10/01/1990 - "No difference in nuclear vV was found in carcinoma in situ with or without co-existing invasion, and no characteristic pattern of nuclear vV was disclosed by following the lesion in serial biopsies over time from individual patients. "
03/01/1977 - "The possible co-existence of proliferative and non-proliferative epithelial compartments in dysplasia and in carcinoma in situ of the uterine cervix is suggested."
08/01/2012 - "To establish the role of co-overexpression of bcl-2 and cerbB- 2/neu protooncogenes in uterine cervix carcinogenesis, we examined 138 tissue samples of low grade cervical squamous intraepithelial lesions (SIL), high grade SIL, cervical carcinoma in situ and cervical invasive carcinoma, stage IA-IIA (study group) and 36 samples without SIL or malignancy (control group). "
04/01/2015 - "Intravesical induction and maintenance immunotherapy with Bacillus Calmette-Guerin (BCG) is the preferred and most effective agent for patients with high-risk NMIBC (carcinoma in situ and high-grade disease) and reduces both recurrence and progression."
03/01/2011 - "Immunotherapy appears to be most effective in patients with upper-tract carcinoma in situ. "
01/01/2006 - "Immunotherapy appears to be most effective in patients with upper tract carcinoma in situ."
11/01/2001 - "Bacillus Calmette-Guerin (BCG) established immunotherapy as an effective modality for carcinoma in situ of the bladder and remains the most effective agent for treatment. "
04/01/1995 - "Intravesical bacillus Calmette-Guérin (BCG) therapy is highly effective in the therapy of carcinoma in situ of the bladder, but the mechanism of BCG immunotherapy is not clearly understood. "
|2.||Drug Therapy (Chemotherapy)
12/01/1991 - "Intravesical TICE BCG is an effective treatment for bladder carcinoma in situ patients with or without prior chemotherapy."
07/01/2005 - "We determined the short-term and long-term efficacy of bacillus Calmette-Guerin (BCG) and chemotherapy in the treatment of patients with carcinoma in situ (CIS). "
01/12/1985 - "Carcinoma-in-situ of testis eradicated by chemotherapy."
07/01/2005 - "Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials."
05/01/2015 - "It is generally believed that carcinoma in situ is refractory to chemotherapy but specific data are lacking to validate this. "
|3.||Photochemotherapy (Photodynamic Therapy)
02/01/2003 - "Our preliminary data show that whole bladder photodynamic therapy with intravesically applied 5-aminolevulinic acid using a white light source is effective in destroying flat malignant lesions of the bladder such as carcinoma in situ. "
12/01/1991 - "Integral photodynamic therapy may prove to be useful for the treatment of carcinoma in situ of the bladder."
09/01/2010 - "Salvage photodynamic therapy for extended carcinoma in situ of the oesophagus after subtotal oesophagectomy: 2 years follow up."
01/01/2007 - "Photodynamic therapy with methyl aminolevulinate for atypial carcinoma in situ of the penis."
03/01/2004 - "Photodynamic therapy for carcinoma in situ of the anus."
03/01/2002 - "Laser treatment is considered to be effective in treating carcinoma in situ of the penis. "
01/01/2009 - "Optimizing staining protocols for laser microdissection of specific cell types from the testis including carcinoma in situ."
01/01/2009 - "Transoral laser microsurgery for carcinoma in situ of the glottic larynx. "
01/01/2006 - "p53 Mutation analysis of low-grade dysplasia and high-grade dysplasia/carcinoma in situ of the esophagus using laser capture microdissection."
06/01/2002 - "For carcinoma in situ and severe dysplasia, microsurgery, preferably by laser, is proposed. "
08/01/1993 - "Excision biopsy, radiotherapy, and laryngofissure cordectomy have all been used, but the best treatment regimen for glottic carcinoma in situ remains controversial. "
11/01/2009 - "To study the effect of 16 Gy radiotherapy (RT) vs. 20 Gy RT on Leydig cell function in men treated with radiotherapy against carcinoma in situ (CIS) of the testis. "
06/01/1988 - "This study shows that radiotherapy is a highly effective method of management for carcinoma in situ of the glottic region."
01/01/2013 - "There were 2 mucosal complete responses, 1 residual carcinoma in situ and 3 partial endoscopic responses in 9 patients who had endoscopy after radiotherapy. "
01/01/2011 - "With a great incidence of carcinoma in situ on spared testicular parenchyma, scrotal radiotherapy is indicated. "